Drug intelligence / Profile preview

YP7

Development stage: Preclinical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

YP7 is a conventional IgG antibody designed to target Glypican-3 (GPC3), a protein highly expressed in hepatocellular carcinoma (HCC) cells but not in normal adult tissues. It binds to GPC3-positive cells and is subsequently internalized. YP7 has been investigated as a drug carrier, particularly in photoimmunotherapy (PIT) where it was conjugated with IR700. Studies have compared its therapeutic effects and intratumoral distribution with a heavy-chain antibody, HN3, for HCC therapy.

Targets

GPC3 (Glypican-3)

Beyond the preview

Go deeper on YP7.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YP7.

Explore the full profile